|
|
|
CONGRESS PROGRAM:
♦SUNDAY ♦ MONDAY
♦TUESDAY ♦WEDNESDAY
♦ THURSDAY♦
The 11th International Congress on Antiphospholipid Antibodies will
present new and original developments in the area of Antiphospholipid
Syndrome.Congress
Lectures and abstracts will be published in a special issue of Thrombosis
Research
that will be availible at the start of the congress.
For a PDF printable version of the congress program click
here.
For a free download of Adobe Reader click
here. 
PRECONFERENCE
WORKSHOP: SUNDAY 14TH NOVEMBER
14.25-18.10 (supported
by an unrestricted grant from the American Autoimmune Related Diseases
Associated Inc. (AARDA)
Update on the International Classification
Criteria for the Antiphospholipid Syndrome
|
14.30-14.40
Ricard Cervera
14.40-14.50
Discussion
|
CARDIAC MANIFESTATIONS
Ricard
Cervera, Yehuda Shoenfeld, Ricardo Forestiero |
|
14.50-15.00
Ware Branch
15.00-15.10
Discussion |
OBSTETRIC MANIFESTATIONS, PREGNANCY AND MORBIDITY CRITERIA
(A) PRE-ECLAMPSIA (B) HELP SYNDROME (C) INTRAUTERINE GROWTH
RETARDATION
Ware Branch,
Roger Levy, Ron Derksen
|
|
15.10-15.20
Robin Brey
15.20-15.30
Discussion
|
NEUROLOGICAL MANIFESTATIONS, STROKE (A) MIGRAINE (B) MULTIPLE
SCLEROSIS-LIKE ILLNESS (C) TRANSVERSE MYELOPATHY (D) COGNITIVE
DYSFUNCTION (E) SEIZURES
Robin Brey,
Joab Chapman, Jacob
Rand, S. Levine
|
|
15.30-15.40
Yehuda Shoenfeld
15.40-15.50
Discussion |
CUTANEOUS MANIFESTATIONS (A) LIVEDO RETICULARIS (B) CUTANEOUS
ULCERS/VASCULITIS
Yehuda
Shoenfeld,
Ricard Cervera
|
|
15.50-16.00
PierLuigi Meroni
16.00-16.10
Discussion
|
RENAL MANIFESTATIONS
PierLuigi
Meroni, Panayiotis Vlachoyiannopoulos |
|
16.10-16.20
Takao Koike
16.20-16.30
Discussion
|
THROMBOCYTOPENIA
Takao Koike,
Pierre Youinou, Benjamin
Brenner |
|
16.30-16.40
Angela
Tincani
16.40-16.50
Guido Reber
16.50-17.00
Discussion
|
DIAGNOSTIC TESTS (A) CURRENT STATUS OF IGA (B) ANTI-BETA2-GLYCOPROTEIN
I
Angela Tincani and
Guido Reber, Robert
Roubey, E Nigel Harris, Silvia Pierangeli |
|
|
|
17.00-17.10
Flip de
Groot
17.10-17.20
Ron Derksen
17.20-17.30
Discussion
|
LUPUS ANTICOAGULANT/BETA2-GPI/PROTHROMBIN/OTHER PROTEIN SPECIFICITIES
Flip de Groot,
Ron Derksen, Tom
Exner, Victoria Regnault, P. de Moerloose |
|
17.30-17.40
Takao Koike
17.40-17.50
Discussion
|
ANTIPROTHROMBIN ANTIBODIES
Takao Koike,
Monica Galli, Joyce Rauch, T. Atsumi |
|
17.50-18.00
Michael
Lockshin
18.00-18.10
Discussion
|
Summary of how well the criteria work so far and what are
the problems
Michael Lockshin
|
8.25-18.08 MONDAY NOVEMBER 15 2004
IMMUNE MEDIATED
MECHANISMS OF THROMBOSIS
CHAIRPERSONS
– SA KRILIS, T. KOIKE
|
8.25 |
Welcome
Speech
S.A. Krilis, Australia
|
|
8.30 |
B CELL
BIOLOGY, APOPTOSIS, AND AUTOANTIBODIES TO PHOSPHOLIPIDS
M. Cook, Australia
|
|
8.55 |
THE IMPACT
OF THE INFLAMMATORY RESPONSE ON COAGULATION
C. Esmon, United
States
|
|
9.20 |
INFLAMMATORY
RESPONSE AND THE ENDOTHELIUM
PL Meroni, Italy |
BETA
2-GLYCOPROTEIN I
|
9.45 |
BETA 2
GLYCOPROTEIN I -FUNCTION IN HEALTH AND DISEASE
S. Krilis,
S.
Miyakis, Australia
|
|
10.10 |
B2-GLYCOPROTEIN
I: ANTIPHOSPHOLIPID SYNDROME AND T-CELL REACTIVITY
M. Kuwana, Japan |
|
10.35
|
COFFEE
BREAK
|
ANTIPHOSPHOLIPID
SYNDROME
CHAIRPERSONS
– EN HARRIS, R. ROUBEY
|
10.50 |
PRIMARY,
SECONDARY, CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME: IS THERE
A DIFFERENCE?
EN Harris, SS Pierangeli,
United States
|
| 11.10 |
PRIMARY
ANTIPHOSPHOLIPID ANTIBODY SYNDROME AS A MODEL OF B CELL-INDUCED
AUTOIMMUNE DISEASE
P. Youinou,
France |
|
|
| 11.30 |
CELL SIGNALLING
PATHWAYS UNDERLYING PATHOGENIC AUTOIMMUNITY
M. Zouali,
France |
|
11.50 |
ANTI-PHOSPHOLIPID
ANTIBODIES AND APOPTOSIS
J. Rauch, R. Subang, JS Levine,
Canada |
|
12.10 |
ANTIBODY-MEDIATED
INTERFERENCE WITH ANNEXINS IN THE ANTIPHOSPHOLIPID SYNDROME
J. Rand, X-X Yu, United States |
| 12.30 |
MECHANISMS
OF AUTOANTIBODY- INDUCED MONOCYTE TISSUE FACTOR EXPRESSION
R. Roubey, AS Wolberg, United States |
|
12.50 LUNCH
& POSTER VIEWING
CHAIRPERSONS – J. MCINTYRE,
SS PIERANGELI, S. LEVINE |
|
13.50 |
EFFECTS
OF FLUVASTATIN ON UPREGULATION OF TISSUE FACTOR BY ANTIPHOSPHOLIPID
ANTIBODIES ON ENDOTHELIAL CELLS
SS Pierangeli,
DE Ferrara, R. Swerlick,
M. Vega-Ostertag, K. Casper,PL Meroni, EN Harris |
|
14.02 |
CONCORDANCE
AMONG APL ASSAYS IN ISCHEMIC STROKE: A SUBSET ANALYSIS OF THE
WARSS/APASS COLLABORATION
SR Levine, RL Brey, BC Tilley, JLT Thompson,
RL Sacco, PA Padilla,
E Du, JP
Mohr, &
The APASS Investigators, United States/Italy |
|
14.14 |
COMPLEMENT
C5 ACTIVATION MEDIATES ANTIPHOSPHOLIPID-INDUCED THROMBOSIS
SS Pierangeli,
ME Vega-Ostertag, G. Giradi,
X. Liu, JE
Salmon, United States
|
|
14.26 |
ANTIPHOSPHOLIPID-INDUCED
THROMBOSIS IS MEDIATED BY GPIIB/IIIA IN PLATELETS IN AN IN VIVO
MOUSE MODEL
M. Vega-Ostetag, FL Pianciola,
A. Liu, V. Henderson, EN Harris, SS Pierangeli, United States |
| |
|
14.38 |
EFFECT
OF BETA 2-GLYCOPROTEIN I NULL MUTATION ON REPRODUCTIVE OUTCOME
AND ANTIPHOSPHOLIPID ANTIBODY-MEDIATED PREGNANCY PATHOLOGY IN
MICE
T. Shi, S. Robertson, C. Roberts,
D. Bjeiring, k. pensa, y. Sheng, S.
Krilis, Australia |
|
14.50 |
ANTI-BETA2GLYCOPROTEIN
I ANTIBODIES POTENTIATE THE INHIBITORY EFFECTS OF BETA2GLYCOPROTEIN
I ON THE ACTIVATION OF FXI BY FIIa:
EFFECTS OF CLIPPED BETA2GLYCOPROTEIN I
Q. Yang, T. Shi, C. Bester, B. Giannakopoulos,
S. Krilis, Australia |
|
15.02 |
BETA2-GLYCOPROTEIN
I BINDS FXI BY ITS C-TERMINAL DOMAIN & INHIBITS ITS ACTIVATION
BY THROMBIN & FXIIa. PLASMIN CLEAVAGE OF B2-GPI ABOLISHES
ITS INHIBITION OF FXIIa ACTIVATION OF FXI
C. Bester, T. Shi,
GM Iverson, KA Cockerill, MD Linnik, P. Konecny, S. Krilis, Australia/United States |
|
15.14 |
BETA2-GLYCOPROTEIN
I BINDS FXI & INHIBITS ITS ACTIVATION BY THROMBIN AND FXIIa:
LOSS OF INHIBITION BY CLIPPED B2-GPI
C. Bester, T. Shi,
Q. Yang, B. Giannakopoulos, GM Iverson, JC Qi, KA Cockerill,
MD Linnik, P. Konecny, S. Krilis,
Australia/ United States |
|
15.26 |
ANTIPHOSPHOLIPID
ANTIBODIES DECREASE PLAQUE FORMATION IN ATHEROSCLEROSIS-PRONE
MICE
M. Monestier, D. Nicolo,
S-A Kang, United States |
|
15.38 |
ANTIPHOSPHOLIPID
SYNDROME NEPHROPATHY IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS
WITH ANTIPHOSPHOLIPID ANTIBODIES
MG Tektonidou, F. Sotsiou,
L. Nakopoulou, PG Vlachoyiannopoulos,
HM Moutsopoulos, Greece |
|
15.50 |
RITUXIMAB
REDUCES ANTIPHOSPHOLIPID ANTIBODY TITERS & IMPROVES HYPERCOAGULABLE
STATE WITHOUT RECURRENT THROMBOSES: 2-YEARS FOLLOW UP
M. Yamazaki,
Y. Kawashima, A. Asakura, S. Nakao,
Japan |
| |
|
16.02 |
THE ANTIPHOSPHOLIPID
SYNDROME: IMMUNOLOGICAL AND CLINICAL ASPECTS
TM Reshetnyak, EN Alexandrova, IB Shtivelband, LV Kondrateva, AA Novikov, LA Kalashnikova, TA Lisitsyna, IE Shirokova, ZS Alekberova, EL Nassonov,
Russia
|
|
16.14 |
ANTIPHOSPHOLIPID
ANTIBODIES FOLLOWING VACCINATION WITH RECOMBINANT HEPATITIS
B VACCINE
B. Bozic, T.
Avcin, J. Martinuc, M. Kuhar, S. Cucnik, M. Zupancic, T. Kveder,
B. Rozman, Slovenia
|
|
16.26 |
COFFEE
BREAK
|
CHAIRPERSONS – Y. SHOENFELD, P.
VLACHOYIANNOPOULOS
|
16.56 |
HEAT SHOCK PROTEIN-60 REACTIVITY IS ASSOCIATED WITH ANTIPHOSPHOLIPID
ANTIBODIES IN VASCULITIS-RELATED AUTOIMMUNE DISEASES
P. Youinou, Y. Renaudinaeu, C. Dugué, J. Arvieux,
R. Perrault, S. Krilis, France/Australia
|
|
17.08 |
HEAT SHOCK PROTEIN REACTIVITY IS ASSOCIATED WITH ANTIPHOSPHOLIPID
ANTIBODIES IN VASCULITIS-RELATED AUTOIMMUNE DISEASE
P. Youinou, C.
Dugué, JC
Piette,
D. Mottier, L. Guillevin, C. Jamin, France
|
|
17.20 |
T LYMPHOCYTE SUBSETS IN PRIMARY ANTIPHOSPHOLIPID SYNDROME
PRJ
Ames, C.
Tommasino, G.
Fossati, LR
Lopez,
E. Matsuura, A. Margarita,
G. Scenna,
V. Brancaccio, Italy/United States/Japan/United
Kingdom
|
|
17.32 |
THE INFECTIOUS ETIOLOGY OF APS: NOVEL CROSS REACTIVE EPITOPES
ON YEASTS, BACTERIA AND VIRUSES
Y. Shoenfeld,
M. Blank, I. Krause, R. Cervera,
J. Font, M.
Torsten,
Israel
|
| 17.44 |
BOTH C4A & C4B NULL ALLELES ARE ASSOCIATED WITH APLIN
CHILDREN WITH IMMUNE THROMBOCYTOPENIC PURPURA
(ITP)
BL Myones,
KAB Marzan, JM Moulds,
United States
|
|
17.56 |
A STUDY OF ANTICARDIOLIPIN ANTIBODIES IN ECLAMPSIA
EG Dachlan, A. Sulistyono,
Indonesia
|
8.30-18.13 TUESDAY
NOVEMBER 16TH 2004
PREGNANCY AND
ANTIPHOSPHOLIPID ANTIBODIES
CHAIRPERSONS
– E. BENSON, RHWM DERKSON
|
8.30 |
GROWTH
AND FUNCTION OF THE NORMAL HUMAN PLACENTA
N. Gude, Australia
|
|
8.55 |
MATERNAL
HEMOSTASIS IN THE NORMAL PREGNANCY
B. Brenner, Israel
|
|
9.20 |
ANTIPHOSPHOLIPID
ANTIBODIES AND FETAL COMPROMISE
DW Branch, United States
|
|
9.40 |
TREATING
OF ANTIPHOSPHOLIPID SYNDROME IN PREGNANCY – A SYSTEMATIC REVIEW
OF THERAPEUTIC TRIALS
MN Lassere, M. Empson
Australia
|
|
10.00 |
IMMUNOLOGIC
MANIPULATION FOR THE THREATENED FOETUS
E. Benson, Australia
|
| 10.20 |
COFFEE
BREAK & POSTER VIEWING |
|
YOUNG INVESTIGATORS
CHAIRPERSONS –
C. ESMON, B. BRENNER, M. ZOUALI |
|
10.50
|
HUMAN MONOCLONAL
IGG ANTICARDIOLIPIN ANTIBODIES INDUCE NITRIC OXIDE SYNTHASE
EXPRESSION
J. Delgado Alves, BR Clapp, R. Stidwill, PP Chen,
AD Hingorani, M Singer,
DA Isenberg, United States
|
|
11.05 |
P38 MITOGEN
ACTIVATED PROTEIN KINASE IS INVOLVED IN UPREGULATION OF TISSUE
FACTOR IN ENDOTHELIAL CELLS BY ANTIPHOSPHOLIPID ANTIBODIES
ME Vega-Ostertag, V. Henderson,
EN Harris, SS Pierangeli,
United States
|
|
11.20 |
ANTIPHOSPHOLIPID
ANTIBODIES CAN REDUCE THE IN VITRO CLEAVAGE
OF DOMAIN V OF
BETA2-GLYCOPROTEIN I BY PLASMIN.
MJ Nash IJ Mackie H. Cohen SJ Machin, United
Kingdom
|
|
11.35 |
INDUCTION
OF ANTIPHOSPHOLIPID SYNDROME IN FACTOR V
LEIDEN MICE
A. Katzav, CG Pick,
M. Blank,Y. Shoenfeld,
J.Chapman
|
|
11.50 |
IDENTIFICATION
OF THE DOMAIN OF BETA2-GLYCOPROTEIN I INVOLVED IN BINDING TO
LRP
M. Van Lummel, RHWM Derksen,
BCH Lutters, E. Westein, PJ Lenting, PhG de
Groot, Netherlands
|
|
12.05 |
IGG’S ISOLATED
FROM PATIENT PLASMA OF APS PATIENTS BIND TO DOMAIN 1 OF BETA2-GLYCOPROTEIN
1
MTT Pennings HB de Laat RHWM Derksen
GM Iverson PhG de Groot,
Netherlands/United States
|
|
12.20 |
ROLES OF
ADHESION MOLECULES IN THE DEVELOPMENT OF THROMBOSIS AND PREGNANT
MORBIDITY IN ANTIPHOSPHOLIPID SYNDROME (APS): STUDIES USING
APS MODEL MICE DEFICIENT OF ADHERENT MOLECULES
M. Yamazaki, Y.
Kawashima,
H. Asakura, S. Nakao, Japan
|
| 12.35 |
LUNCH &
POSTER VIEWING |
| CHAIRPERSONS
– MD LOCKSHIN, PL MERONI, T. BRIGHTON |
| 13.35 |
HOW
MUCH WARFARIN IS ENOUGH IN APS-RELATED THROMBOSIS?
M. Lockshin, D. Erkan, United States |
| 13.50 |
OPTIMAL
THERAPY OF PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES AND THROMBOSIS:
THE NEXT STEPS
M. Crowther, Canada. |
| 14.05 |
APLASA
STUDY UPDATE: PRIMARY THROMBOSIS PREVENTION IN ASYMPTOMATIC APL
(+) PATIENTS WITH ASPIRIN (ASA)
D. Erkan, L. Sammaritano, R. Levy, MJ Harrison, M. Peterson, Y.
Yazici, MD Lockshin, United States/Brazil |
|
14.17 |
RELATIVE
RISK OF BLEEDING AND RETHROMBOSIS IN PRIMARY ANTIPHOSPHOLIPID
SYNDROME AT A TARGET INR OF 2-3. A 9 YEAR COMPARATIVE STUDY
WITH INHERITED THROMBOPHILIA AND MITRAL VALVE REPLACEMENT PATIENTS.
PRJ Ames, A. Ciampa, M. Margaglione, A. Margarita,
L. Iannaccone, G. Scenna, V. Brancaccio,
United Kingdom/Italy
|
|
14.29 |
THE ANTIPHOSPHOLIPID
SYNDROME COLLABORATIVE REGISTRY: INITIAL DESCRIPTION OF THE
STUDY COHORT
RAS Roubey, G. Buxton, The APSCORE
Investigators, United States
|
| 14.41 |
KALLIKREIN
IS ABLE TO SPECIFICALLY CLEAVE BETA2-GLYCOPROTEIN I IN DOMAIN
V
MJ Nash, IJ Mackie, SJ Machin, United
Kingdom |
|
14.53 |
IN-VITRO
STUDY OF THE EFFECT OF HEPARINS ON TROPHOBLAST PROLIFERATION
C. McLintock, L. Chamley,
A. Moore, P. Stone,
New Zealand
|
|
15.05 |
BETA 2-GLYCOPROTEIN
I DEPENDENT LUPUS ANTICOAGULANT HIGHLY CORRELATES WITH THROMBOSIS
IN THE ANTIPHOSPHOLIPID SYNDROME
HB de Laat, RHWM Derksen,
RT Urbanus, M. Roest, PhG
de Groot, Netherlands
|
|
15.17 |
PATHOGENIC
ANTI-BETA2-GLYCOPROTEIN I ANTIBODIES RECOGNIZE A POSITIVE CHARGED
EPITOPE ON DOMAIN I
HB de Laat, RHWM Derksen,
RT Urbanus, GM Iverson, PhG de Groot, Netherlands/United States
|
|
15.29 |
THE EFFICACY
AND SPECIFICITY OF ANTI-ANTI- BETA-2GPI-IVIG FRACTION IN-VITRO
AND IN AN ANIMAL MODEL.
Y. Shoenfeld,
M. Blank, L. Ashkenazi, I. Nur, L.
Bar, Israel
|
| 15.41 |
FLUVASTATIN
INCREASES THE EXPRESSION OF ADHESION MOLECULES, MCP-1 AND TISSUE
FACTOR IN HUVEC STIMULATED BY ANTIPHOSPHOLIPID ANTIBODIES
G. Reber, S. Dunoyer-Geindre, RJ Fish, N. Satta, EKO Kruithof, P. de Moerloose, Switzerland |
TUESDAY
NOVEMBER 16TH 2004
CHAIRPERSONS- J. RAUCH, DW
BRANCH, M-C BOFFA
|
15.53 |
ARE ENDOTHELIAL
MARKERS ASSOCIATED WITH NEW THROMBOSIS?
C. Neville,
S. Solymoss, J. Rauch, J. Kassis,
L. Joseph, P. Belisle, E. Chang, R.
Subang, M. Le Comte, PR Fortin, Canada
|
|
16.05 |
COFFEE BREAK
|
|
16.25 |
PHOSPHATIDYLSERINE
DEPENDENT ANTIPROTHROMBIN ANTIBODIES ARE NOT USEFUL FOR IDENTIFICATION
WITH A HIGH RISK OF PATIENTS SUFFERING FROM RECURRENT MISCARRIAGES
MS Sugiura-Ogasawara, TA Atsumi,
KK Katano,YO Ozaki, TN Nakanishi,
TK Koike, KS Suzumori, Japan
|
|
16.37 |
THROMBOTIC
AND VASCULAR EVENTS IN BABIES BORN TO MOTHERS WITH APS
OR APLA
MCBoffa, E. Lachassinne, MH Aurousseau,
M. Uzan, O. Fain,
R. Rai, S.
Sangle, T. Avcin, D. Farge, P. Douart, JC Piette, L. Regan,
GRV Hughes, France/UnitedKingdom
|
|
16.49 |
IGG ANTICARDIOLIPIN
ANTIBODY PROFILE ON SEVERE PREECLAMPSIA
A. Sulistyono, EG Dachlan, Indonesia
|
|
17.01 |
ARE ANTIPHOSPHOLIPID
ANTIBODIES CONCENTRATED IN FOLLICULAR FLUID?
LW
Chamley, AM
Moore, PR
Stone, New Zealand
|
|
17.13 |
ANTIPHOSPHOLIPID
ANTIBODIES IN THE FOLLICULAR FLUID AND IVF OUTCOME
LW
Chamley, K. Buckingham, PR Stone, New Zealand
|
|
17.25 |
ANTIPHOSPHOLIPID
ANTIBODIES AND THROMBOPHILIA IN WOMEN WITH RECURRENT ABORTION
AND FETAL LOSS. OUTCOME OF THERAPY WITH HEPARIN OR LMWH IN COMBINATION
WITH ASPIRIN
KLT
Tambunan, EW
Wijono, NK
Kampono, EJS
Suryana, JJE Endjun,
JW Witjaksono, Indonesia
|
TUESDAY NOVEMBER 16TH 2004
|
17.37 |
ANTIBODIES
TO TFPI IN WOMEN WITH PREGNANCY
MORBIDITY
OR IMPLANTATION FAILURES
RR
Forastiero, ME
Martinuzzo, ML
Iglesias
Varela, YP Adamczuk, GJ
Broze, Argentina/United States
|
|
17.49 |
ANTIPHOSPHOLIPID
ANTIBODIES AND CEREBROVASCULAR ACCIDENTS IN PATIENTS UNDER 50
B. Owlia, Z. Dehghani, F. Fallah, Iran |
|
18.01 |
ATHEROSCLEROSIS
IN PRIMARY ANTIPHOSPHOLIPID SYNDROME
PRJ Ames, A. Margarita, L. Iannaccone,
G. Scenna, United Kingdom/Italy |
8.30-13.18 WEDNESDAY NOVEMBER
17TH 2004
PATHOPHYSIOLOGICAL
MECHANISMS
CHAIRPERSONS
– PhG de GROOT, J. RAND
|
8.30 |
PLATELET
PHYSIOLOGY AND THROMBOSIS
RK
Andrews, EE
Gardiner,
JF Arthur, MC Berndt, Australia
|
|
8.55 |
b2-GLYCOPROTEIN I AND LDL-RECEPTOR
FAMILY MEMBERS
PhG
de Groot, M. van Lummel,
M. Pennings, R.
Urbanus, HB
de Laat, PJ Lenting, RHWM
Derksen,
Netherlands
|
|
9.20 |
b2-GLYCOPROTEIN I, ANTI-ß2-GLYCOPROTEIN
I AND FIBRINOLYSIS
S.
Yasuda, T.
Atsumi, T.
Koike, Japan
|
|
9.40 |
INTRACELLULAR
SIGNALING TRIGGERED BY ANTIPHOSPHOLIPID ANTIBODIES IN PLATELETS
AND ENDOTHELIAL CELLS: A PATHWAY TO TARGETED THERAPIES
SS
Pierangeli, ME
Vega-Ostertag, EN
Harris,
United States
|
CNS AND CARDIOVASCULAR MANIFESTATION OF
APS
|
10.00 |
THE INTERFACE
OF MULTIPLE SCLEROSIS AND ANTIPHOSPHOLIPID ANTIBODIES
J. Chapman, Israel
|
|
10.20 |
CONTROVERSIES
IN THE ANTIPHOSPHOLIPID SYNDROME AND STROKE
PA Gatenby, Australia
|
|
10.40 |
MANAGEMENT
OF THE NEUROLOGICAL MANIFESTATIONS OF APS – WHAT DO THE TRIALS
TELL US?
RL
Brey, United States
|
|
11.00 |
CORONARY
AND VALVULAR SYNDROMES AND ANTIPHOSPHOLIPID ANTIBODIES
R.
Cervera, Spain
|
| 11.20 |
PERIPHERAL
VASCULAR DISEASE IN ANTIPHOSPHOLIPID SYNDROME
PG Vlachoyianopoulos, Greece |
WEDNESDAY NOVEMBER 17TH 2004
CHAIRPERSONS – R. CERVERA,
ROBIN L. BREY
|
12.00 |
ASSOCIATION
OF SEVERE VALVULAR REGURGITATION WITH ANTIPHOSPHOLIPID ANTIBODIES
IN SYSTEMIC LUPUS ERYTHEMATOSUS
R.
Cervera, J.
Font,
F.
Pérez-Villa, M.
Azqueta,
C.
Paré,
G.
Espinosa,
JC
Reverter,
M. Ramos-Casals,
M.
Ingelmo,
G.
Sanz, Spain
|
|
12.12 |
RISK FACTORS
FOR COGNITIVE DYSFUNCTION IN SLE: SAN ANTONIO LUPUS STUDY OF
NEUROPSYCHIATRIC DISEASE
SL Holliday,
AR Saklad, R.
Garcia-Cavasos, M.
Fischbach, PA
Padilla,
D. McGlasson, RL
Brey, United
States
|
|
12.24 |
ANTIPHOSPHOLIPID
ANTIBODY (APL) IN SERUM AND CSF FROM PATIENTS WITH PSYCHOSIS
RS O'Brien, DK Sokol, DR Wagenknecht, TV Rao, JA McIntyre, United States
|
|
12.36 |
APS EXACERBATES
AMYLOID DEPOSITION AS WELL AS MEMORY IMPAIRMENT IN AN ANIMAL MODEL
OF ALZHEIMER’S DISEASE
A.
Katzav, CG
Pick, DM
Michaelson, M.
Blank, Y.
Shoenfeld,
J. Chapman, Israel
|
|
12.48 |
MECHANISMS
OF NEURONAL DAMAGE IN SLE AND APLS: THERAPEUTIC IMPLICATIONS
JA
Denburg, MM
Sidor, MM
Cyr, D.
Ballock, L.
Doering, H.
Szechtman, B.
Sakic, Canada
|
| 13.03 |
PHOSPHOLIPID
ANTIBODIES AND COGNITIVE FUNCTION: PATTERNS AND PREDICTION
SD Denburg, JA
Denburg, Canada |
Wednesday 17th November
|
14.00-1600
|
HARBOUR CRUISE WITH LATE LUNCH AND AUSTRALIAN WINES
AND BEER.
Start the afternoon with a short walk to the steps of
the Opera House where you will embark on a state of the art trimaran
for a leisurely cruise around one of the most admired harbours
in the world. During the cruise partake of the best of Australian
wines, beers and a light lunch. |
|
19.30-11.30
|
CONGRESS BANQUETAll Ticket Holders |
8.30-17.48 THURSDAY NOVEMBER
18TH 2004
MEASUREMENT OF
AUTOANTIBODIES IN APL, WHICH ONES?
CHAIRPERSONS
– T. EXNER, R. LEVY
|
8.30 |
TESTS FOR
LUPUS ANTICOAGULANT REVISITED
RHWM
Derksen, PhG
de Groot,
Netherlands
|
|
8.55 |
ANTI-ß2-GLYCOPROTEIN
I ANTIBODIES – WHEN AND
HOW SHOULD THEY BE MEASURED ?
G. Reber, P. de
Moerloose, Switzerland
|
|
9.20 |
ANTIPROTHOMBIN
ANTIBODIES – ARE THEY WORTH ASSAYING ? –
T.
Atsumi, O.
Amengual, S.
Yasuda,
T.
Koike, Japan
|
|
9.45 |
PHENOTYPING
THE HAEMOSTATIC SYSTEM BY THROMBOGRAPHY – PROSPECTS TO THE ESTIMATION
OF THE THROMBOTIC RISK
V. Regnault, HC Hemker, D. Wahl, T.
Lecompte, France/Netherlands
|
CHAIRPERSONS – A. TINCANI, J. MCINTYRE
|
10.30 |
DETECTION
OF PROCOAGULANT PHOSPHOLIPID INTERFERING IN TESTS FOR LUPUS
ANTICOAGULANT
T.
Exner, J.
Low, Australia
|
|
10.45 |
MINIMAL
REQUIREMENTS OF APL ELISAS
A. Tincani, F. Allegri,
G. Balestrieri, G. Reber,
M. Sanmarco, PL Meroni,
MC Boffa, Italy/Switzerland/France
|
|
11.00 |
CONSENSUS
GUIDELINES FOR ANTICARDIOLIPIN ANTIBODY TESTING
RCW Wong, Australia
|
|
11.20 |
ASSESSMENT
OF THE ROLE OF ANTICARDIOLIPIN ANTIBODY TEST IN DIAGNOSIS OF
THE ANTIPHOSPHOLIPID SYNDROME
EN Harris, SS Pierangeli,
United States
|
THURSDAY NOVEMBER 18TH 2004
|
11.35 |
AN ADAPTED ELISA METHOD
FOR DIFFERENTIATING PATHOGENIC FROM NON-PATHOGENIC APL BY A b2-GLYCOPROTEIN I DEPENDENCY ANTI-CARDIOLIPIN ASSAY.
RA Levy, E.
de Meis, SS Pierangeli, Brazil/United
States
|
|
11.50 |
THE APPEARANCE
AND DISAPPEARANCE OF APL AUTOANTIBODIES SUBSEQUENT TO OXIDATION
– REDUCTION (REDOX) REACTIONS
JA McIntyre, United States
|
|
12.10 |
LIBMAN-SACKS ENDOCARDITIS
ASSOCIATED WITH ANTIPHOSPHOLIPID SYNDROME AND INFECTION
Y. Shoenfeld, M. Blank, A. Shani, I. Goldberg, J. Kopilovic,
MC Amigo, L. Magrini, Israel/Mexico/Italy
|
| 12.30 |
LUNCH
& POSTER VIEWING |
CHAIRPERSONS – M. GALLI, SS PIERANGELI
|
13.30 |
ANTIPHOSPHOLIPID
ANTIBODIES ARE A RISK FACTOR FOR MYOCARDIAL INFARCTION (BUT
NOT ATHEROSCLEROSIS): HOPKINS LUPUS COHORT
M. Petri, United States
|
|
13.50 |
ANTIPHOSPHOLIPID
ANTIBODIES AND THROMBOSIS: DO TEST PATTERNS IDENTIFY THE PATIENTS’
RISK?
M. Galli, Italy
|
|
14.10 |
REAL WORLD
EXPERIENCE WITH ANTIPHOSPHOLIPID ANTIBODIES(APL): HOW STABLE ARE APL OVER TIME?
W. Derksen, D.
Erkan, V. Kaplan,
L. Sammaritano, SS Pierangeli,
MD Lockshin, Netherlands/United States
|
|
14.22 |
REAL WORLD
EXPERIENCE WITH APL: COMPARISON BETWEEN APS AND ASYMPTOMATIC
APL-POSITIVE PATIENTS
W. Derksen, D.
Erkan, V. Kaplan,
L. Sammaritano, MD Lockshin,
Netherlands/United States
|
THURSDAY NOVEMBER 18TH 2004
|
14.34 |
CLINICAL
SIGNIFICANCE OF PHOSPHATIDYLSERINE-DEPENDENT ANTIPROTHROMBIN ANTIBODY (APS/PT) BOUND ONLY
TO HUMAN PROTHROMBIN IN APS PATIENTS WITH SEVERAL KINDS OF COLLAGEN
DISEASE
Y. Kawashima, M. Yamazaki, H. Asakura, E. Morishita, S. Otake, Japan
|
|
14.46 |
REPORT
ON THE EUROPEAN COLLABORATIVE STUDY ON ANTIPHOSPHATIDYLETHANOLAMINE
ANTIBODIES
M.
Sanmarco, S. Gayet, MC Alessi, M. Audrain, B.
Boneu, E. de Maistre, JC Gris, P. de Groot, E. Hachulla,
I. Kontopoulou-Grivas, P. Sié,
France/Netherlands/Greece (European Forum on aPL)
|
|
14.58 |
RELATIONSHIP
BETWEEN ANTI-PROTEIN S (ANTI-PS) AND ANTI- PHOSPHATIDYLETHANOLAMINE
(APE) ANTIBODIES IN PATIENTS WITH CLINICAL FEATURES OF ANTIPHOSPHOLIPID
SYNDROME (APS)
M. Sanmarco, N. Bardin, P. Roll, MC Alessi,
France
|
|
15.10 |
THE PREVALENCE
AND CLINICAL SIGNIFICANCE OF IGA ANTIPHOSPHOLIPID ANTIBODIES
YP Shen, AM Dyszkiewicz-Korpanty,
R. Lee, J.
Balani, EP Frenkel, R. Sarode, United States
|
| 15.22 |
COFFEE
& POSTER VIEWING |
CHAIRPERSONS – G. REBER, I. MACKIE
|
16.00 |
ASSOCIATION
OF HIGH AVIDITY ANTI-BETA2GPI ANTIBODIES WITH THROMBOSIS IN
PATIENTS WITH APS
B. Božič, S.
Cucnik, T. Kveder, B. Rozman, Slovenia
|
|
16.12 |
EVALUATION
OF TEN COMMERCIAL ASSAYS FOR THE QUANTITATION OF ANTI-B2GLYCOPROTEIN
I ANTIBODIES. ON BEHALF OF THE STANDARDISATION GROUP OF THE
EUROPEAN FORUM ON ANTIPHOSPHOLIPID ANTIBODIES
G. Reber, M. Sanmarco, A. Tincani,
P. de Moerloose, MC
Boffa,
Switzerland/France
|
| 16.24 |
LABORATORY
DIAGNOSIS OF LUPUS ANTICOAGULANT IN PATIENTS ON ORAL ANTICOAGULANT
M. Aboud, CM Ward,
L. Coyle, Australia |
THURSDAY NOVEMBER 18TH 2004
|
16.36 |
DOES HEPARINASE
TREATMENT OF PLASMA AFFECT THE DETECTION OF LUPUS ANTICOAGULANTS?
C. Brookfield, G.
Jowitt, K. Goodfellow,
S. Kitchen, United Kingdom
|
|
16.48 |
PROLONGED
BLEEDING TIME AND LUPUS ANTICOAGULANT: A SECOND PARADOX IN
THE ANTIPHOSPHOLIPID SYNDROME
RT Urbanus, HB de
Laat, PhG de
Groot, RHWM Derksen, Netherlands
|
|
17.00 |
A PROTOTYPE
COMMERCIAL ELISA FOR PROTEIN S ANTIBODIES
IJ Mackie, HB de Laat, G. Purdy,
M. Adam, B. Woodhams, RHWM Derksen,
PhG de Groot, United
Kingdom/Netherlands/France
|
|
17.12 |
THROMBOGRAPHY
ALLOWS RELIABLE STUDY OF THE PROTEIN
C SYSTEM IN APS AND EVIDENCES A STRONG PHENOTYPIC HETEROGENEITY
D. Wahl, V. Regnault, S. Béguin, E. de
Maistre, P.
Kaminsky, HC Hemker,
T. Lecompte, France/Netherlands
|
|
17.24 |
DOES SLE
AFFECT THE OUTCOME IN CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME
(CAPS)?
D. Erkan, R. Asherson, R. Cervera,
G. Espinosa, S. Bucciarelli, JA Gómez-Puerta, J. Font,
United States/South Africa/Spain
|
|
17.36 |
ASSESSMENT
OF PLATELET FUNCTION UNDER FLOW CONDITION IN PATIENTS WITH
SCLERODERMA AND ANTIPHOSPHOLIPID SYNDROME USING THE CONE AND
PLATE(LET) ANALYZER
D.
Varon, Y. Levy, B. Shenkman,
R. Pauzner, Y. Shoenfeld, N.
Savion, Israel
|
|
17.48 |
OBSTETRICAL
APS: HEPARIN DOSING BASED ON PHARMACOKINETICS
MD Stephenson,
MHH Ensom, Canada |
POSTERS
MONDAY
15 NOVEMBER 2004 Posters
8.30am to 5.30pm |
| [1] |
Are Acquired
Activated Protein C Resistance (APCR) and Hyperhomocysteinemia
Associated
with New Thrombosis?
Canada |
J. Kassis, C. Neville, S. Solymoss, E. Chang, J. Rauch,
L. Joseph,
P. Belisle, M. Le
Comte, R. Subang, PR Fortin |
| [2] |
Two Adolescents
with Neurological Abnormalities and Elevated Antiphospholipid
Antibodies
United
States |
A. Gedalia, H. Sinclair,
S. Deputy, W. Wilson |
| [3] |
Antiphospholipid
and antinuclear antibodies following infliximab
treatment in patients with ankylosing spondylitis.
Italy |
F. Atzeni,
P. Sarzi-Puttini, G. Randisi, MG Marrazza, M. Carrabba, F.
Capsoni |
| [4] |
Elevated
Levels Of Baff Correlate With Antiphospholipid Antibody Production
In Systemic Lupus Erythematosus
France |
B. Bendaoud, Y. Pennec,
A. Saraux,
Y. Renaudineau,
C. Jamin,
P. Youinou |
| [5] |
Prevalence
of Antiphospholipid Antibodies in Rheumatoid Arthritis
Israel/Italy |
Y. Sherer, R. Gerli,
R. Allegrucci, A. Giordano, B. Gilburd,
G. Vaudo, S. Marchesi, G. Schiallaci,
E. Mannarino, Y. Shoenfeld |
| [6] |
Thickened
Carotid Artery Intima-Media in Rheumatoid Arthritis Patients
is Associated With Elevated Anti-Cardiolipin Antibodies
Israel/Italy |
Y. Sherer, R. Gerli,
R. Allegrucci, A.Giordano,
B. Gilburd, G. Vaudo,
S. Marchesi, G. Schillaci, E. Mannarino, Y. Shoenfeld |
|
[7] |
Rapidly
progressed mononeuritis multiplex in a case of central nervous
system lupus associated with lupus anticoagulant.
Japan |
A. Goto, M. Mukai,
A. Notoya, H. Takashima,
T. Fukuda, M.
Kaji, S. Kaieda, K. Tanaka, R.
Ayukawa |
| [8] |
Antiphosphatidylethanolamine antibodies in
patients with Sneddon’s syndrome
Russia |
LA Kalashnikova, LA Dobrynina. EA Aleksandrova, AA Novikov,
EL Nassonov,
EV Sergeeva, AL Berkovskiy |
| [9] |
Antibodies to
myelin basic protein, glial fibrillary acidic protein and neurospecific
enolase in patients with primary antiphospholipid syndrome and
nervous system involvement
Russia |
LA Kalashnikova, OI
Gurina, VP Chehonin, BD Dzhamantaeva, LA Dobrynina, EA
Aleksandrova,
AA Novikov |
|
[10] |
Register
of babies born to mothers with APS. First immunological results
France/Slovenia/Italy |
MH Aurousseau,
E. Lachassine, H.
Dauphin, O. Fain, M. Uzan, P. Le Toumelin, S. Derenne, C. Boinot,
T. Avcin,
M. Motta,
D. Faden,
A. Tincani,
JC Piette, MC Boffa
|
|
[11] |
Evaluation
Of Efficacy And Tolerability Of A Fixed Dose Combination Of
Losartan And Ramipril In The Management Of Hypertensive
Patients With Associated Diabetes Mellitus : Lord Trial (Losartan
Ramipril in Diabetic Hypertensives)
India |
D. Pawar,
S. Joshi, M. Yeolekar, K.Tripathi, J.Giri, A. Maity,
M Chopda,
S Maroli |
| [12] |
A Post
Marketing Surveillance Of Telmisartan
In Indian Hypertensive Patients
India |
D. Pawar, M. Yeolekar,
M. Chopda, S. Maroli, V.
Mourye |
| [13] |
HLA Associations Of Anti-Annexin V,
Anti-Prothrombin, Anti-Beta2GPI, Anti-Protein C And Anti-Protein
S Antibodies In Systemic Lupus Erythematosus
Italy/Spain |
M. Galeazzi,
G. Morozzi, GD Sebastiani,
F. Bellisai, R. Cervera, E. de
Ramon Garrido,
A. Fernandez
Nebro, O. De Pità |
|
[14] |
The Relationship
Of OXLDL, ß2GPI and ß2GPI-OXLDL Complexes In Patients With APS
Slovenia |
A. Ambrozic, T.
Kveder, B. Rozman,
E. Matsuura |
|
[15] |
High Levels
Of Antibodies To CMV And To CMV-Peptide In Sera Of APS Patients.
United
States |
K. Labat,
M. Vega-Ostertag, SS Pierangeli,
AE Gharavi |
|
[16] |
A Peptide
Derived From Cytomegalovirus Reverses Thrombosis Induced By
Antiphospholipid Antibodies.
United
States |
M. Vega-Ostertag, X. Liu, V. Henderson, AE Gharavi, SS Pierangeli |
| [17] |
Upregulation of Expression Of IL-6 and
IL-8 In Endothelial Cells By Antiphospholipid Antibodies.
United
States |
M. Vega-Ostertag, M. Lindsay, K. Labat, EN Harris,
SS Pierangeli |
| [18] |
Factor
V Leiden (G1691A), prothrombin (G2021A) and 5,10-methylentetrahydrofolatereductase
(C677T) gene mutations in patients with primary antiphospholipid
syndrome (PAPS) and cerebrovascular disease
Russia |
LA Kalashnikova,
NLPatrusheva, LI Patrushev,
T. Kovalenko, LA Dobrynina,
EN Aleksandrova, EL Nassonov
|
| [19] |
Differences
in Myocardial Involvement in Primary Versus Secondary Antiphospholipid
Syndrome
Greece |
I. Moyssakis, NJ Pantazopoulos,
M. Tektonidou, D. Papadopoulos,
E. Gialafos, V. Votteas |
| [20] |
Right Ventricular
Performance Index in Patients with Antiphospholipid Syndrome
and Pulmonary Hypertension
Greece |
I. Moyssakis, NJ
Pantazopoulos,
E. Gialafos, M. Tektonidou, V. Vassiliou, V. Votteas |
| [21] |
Heart
Lesions in Patients with Systemic Lupus Erythematosus. Influence
of Antiphospholipid Antibodies.
Greece |
I. Moyssakis,
NJPantazopoulos,
M. Tektonidou, E. Gialafos, P. Vlahoyannopoulos, V. Votteas |
| [22] |
The
condition of mucous stomach in systemic lupus erythematosus
(SLE) patients and APS patients.
Russia |
TM Reshetnyak, IA Doroshkevich,
AE Karateev, SG Radoneska-Lapovok,
AV Novikova, LV Kondratieva,
EL Nassonov |
|
[23] |
Acute
Respiratory Distress Syndrome In The Catastrophic Antiphospholipid
Syndrome
Spain/South
Africa |
S. Bucciarelli,
R. Cervera, G.Espinosa,
JA Gómez-Puerta, Gclaver, M. Ramos-Casals,
M. Ingelmo, J. Font, RA Asherson
|
| [24] |
Anti
Phospholipid Antibody Syndrome Presenting As Retinal Vein Occlusion
India |
F. Manuel, G. Rajasekhar,
LM Christina, S.Anandan, S. Premalatha,
S. Shobana, V. Mahalakshmi,
R. Sudha, M. Rashmi,
S. Murugan, S. Adikrishnan |
| [25] |
Effect
of anti beta2-glycoprotein I lupus anticoagulant antibodies on
clotting time in the presence of human umbilical vein endothelial
cells. |
A.Banzato,
A.Biasiolo,A.Rosato.V.Pengo |
| [26] |
Thrombotic
thrombocytopenic purpura in two patients with antiphospholipid
syndrome Japan
|
Y. Kon, T. Atsumi,
M. Kondo,Y. Sakai. S. Yasuda, Y. Amasaki, T. Koike
|
|
[27] |
OxLDL/b2GPI
complexes in type II Diabetes Mellitus United
States/Japan
|
LR
Lopez, B. Hurley,
J. Kuca, K. Dier, C.
Fink, E. Matsuura |
|
[28]
|
Prevalence
of Antiphospholipid Antibodies in a Lupus Inception Cohort: Brain
Connections United States |
RL Brey, SL
Holliday, PA Padilla, N. Naqibuddin, M. Petri |
| [29] |
Long
Term Follow-up of Patients with Phospholipid Antibodies
United States
|
T. Loughran, C. Galea , S.
Lakshminarayanan, A. Parke |
| [30] |
Short
Term Lack Of Efficacy Of Rituximab In A Thrombocytopaenic Patient
With Primary Antiphospholipid Syndrome Italy/United
Kingdom
|
C. Tommasino, G.
Fossati, A. Saulino, A. Margarita, F. Ferrara, L. Iannaccone, V. Brancaccio, PRJ Ames |
| [31] |
Circulating
oxLDL/ß2GPI Complexes in Autoimmune Disease: Pathogenic
Implications for Systemic Lupus Erythematomsus and Systemic Sclerosis |
LR
Lopez,
K. Dier,
B. Hurley, J. Kuca, C. Fink, E. Matsuura |
| [32] |
Antiphospholipid
Syndrome Profile in Hepatitis C Viral Infected Patients with Compensated
Liver Egypt
|
AS Ellabban,
ME
Abd EL-Fattah, T. Motamed |
TUESDAY
16 NOVEMBER 2004 Posters
8.00am to 5.30pm |
| [1] |
Enoxaparin
In Pregnancy Loss Associated With Antiphospholipid Antibodies |
B Grand, A.
Ventura, D. Riveros |
| [2]
|
The role of annexin A5 in the antiphospholipid
syndrome
Netherlands/United
Kingdom/France |
HB de Laat, PhG de Groot, IJ
Mackie, S. Schoormans, M. Adam, G. Purdy,
B. Woodhams, RHWM Derksen,
W. van
Heerde |
| [3]
|
Pregnancy Outcomes in Women with Lupus
Nephritis and Antiphospholipid Antibodies
United States/Czech Republic |
VD. Garovic, D. Reed, M. Sitina,
KG Moder
|
|
[4]
|
Randomized controlled trial of aspirin
and combined aspirin-heparin in antiphospholipid complicated
pregnancy
Indonesia |
J. Witjaksono,
K. Tambunan |
| [5]
|
Annexin V Antibodies and Their Role
in Complications of Pregnancy
United Kingdom |
L. Cooper, A.
Ochert, Y. Tayob,
M. Parry |
| [6]
|
Low Protein Z Concentration In Women
With Early Fetal Losses, A New Tool To Detect APS?
Germany |
F. Bergmann, WN
Kühn-Velten, C. Nolte, G. Dubenhorst, S. Spranger, B. Kazmierczak
|
|
[7]
|
Health-Related Quality of Life and Prospective
Treatment in Antiphospholipid Antibody Syndrome.
United States |
GA McCarty, TE
Cason |
|
[8]
|
Serum Anticardiolipin &Antiphospholipid
Antibodies in patients with autoimmune disorders
Iran
|
A. Naghi, M.
Shaiegan, Mahnaz Aghaiipour |
|
[9]
|
Antiphospholipid and anti-annexin A5
antibodies in patients with recurrent IVF-ET failure and recurrent
pregnancy loss
Japan
|
H. Matsubayashi, M. Shida,
A. Kondo,
T. Sugi,
T. Makino
|
|
[10]
|
Absence of Antibodies to beta2 Glycoprotein1
In Multiple Sclerosis.
Israel |
J. Chapman, M.
Blank, M. Gurevich, Y.
Shoenfeld, A. Achiron |
|
[11]
|
Antiphospholipid syndrome with neurological
symptoms. Case report.
Czech Republic |
D. Jilek, V. Kral,
J. Markova |
|
[12]
|
aPL and the Risk of Stroke and Myocardial
Infarction in German Lupus Patients
Germany |
S. Beer, R.
Fischer-Betz, M. Sitzer,
M.
Schneider
|
|
[13]
|
Prevalence of Cerebral Microembolism in a German SLE-Cohort
Germany
|
S. Beer, R.
Fischer-Betz, M. Sitzer,
M.
Schneider
|
|
[14]
|
The induction of LAC by immunotherapy
with biological response modifier in recurrent miscarriage patients
Japan |
K. Katano, MS Ogasawara, K. Aoki, K. Suzumori
|
|
[15]
|
Antiphospholipid antibodies as a baseline
risk factor for damage development in Systemic Lupus Erythematosus.
Norway
|
A. Becker-Merok, OP
Rekvig, JC Nossent
|
|
[16]
|
Autoimmune hepatitis
– a new manifestation of the Antiphospholipid
antibody syndrome ?
Norway |
A. Becker-Merok, JC Nossent |
|
[17]
|
|
14
- 18 November 2004
